



Curriculum Vitae

Europass

Personal Information

Surname(s) / Name(s) **PASELLO GIULIA**

Nationality Italian

Date of birth 17/10/1979

Gender Female

Tel +390498215608

Email: giulia.pasello@ioveneto.it

Occupational Field Medical Oncology

Work experience

Dates 07/01/2014-current position

Occupation or position held Associate Medical Director

Main activities and responsibilities Clinical and research activity in thoracic oncology

Name and address of employer Second Medical Oncology Unit, Istituto Oncologico Veneto, Via Gattamelata 64, 35128 Padua (Italy)

Type of business or sector Medical Oncology

Dates 01/02/2010- 06/01/2014

Occupation or position held Medical Oncologist (with contract)

Main activities and responsibilities Clinical and research activity in thoracic oncology

Name and address of employer Second Medical Oncology Unit, Istituto Oncologico Veneto, Via Gattamelata 64, 35128 Padua (Italy)

Type of business or sector Medical oncology

Dates 01/07/2009 - 01/12/2009

Occupation or position held Fellow

Main activities and responsibilities	Basic research about malignant pleural mesothelioma
Name and address of employer	Molecular Oncology laboratories, University of Zurich (Switzerland), Prof. Rolf Stahel
Type of business or sector	Molecular Oncology
Dates	01/07/2008 - 31/12/2008
Occupation or position held	Resident in Medical Oncology
Main activities and responsibilities	Clinical management of oncological pediatric patients
Name and address of employer	Pediatric oncohematology, University of Padua (Italy)
Type of business or sector	Pediatric Oncology and Haematology
Dates	01/07/2007 - 31/12/2009
Occupation or position held	Resident in Medical Oncology
Main activities and responsibilities	Clinical management and research in Oncology
Name and address of employer	Second Medical Oncology Unit, Istituto Oncologico Veneto Padua (Italy)
Type of business or sector	Medical Oncology
Dates	01/01/2006 - 30/06/2007
Occupation or position held	Resident in Medical Oncology
Main activities and responsibilities	Basic and translational research in oncology
Name and address of employer	Oncological and Surgical Science Department, Oncology Section, University of Padua (Italy)
Type of business or sector	Molecular Oncology
Education and Training	
Dates	01/01/2012-31/12/2014
Title of qualification awarded	PhD
Principal subjects/occupational skills covered	Neoangiogenic biomarkers and therapeutic targets in malignant pleural mesothelioma
Dates	01/01/2006 - 31/12/2010

Title of qualification awarded	Residency in Medical Oncology
Principal subjects/occupational skills covered	Medical Oncology
Name and type of organisation providing education and training	University of Padua (Italy)
Dates	01/10/1999 - 11/10/2005
Title of qualification awarded	Graduation in medicine and surgery
Name and type of organisation providing education and training	University of Ferrara (Ferrara, Italy)
Other training experiences	March 2014: admitted at the 13th ESO ESMO Masterclass in Clinical Oncology where she attended plenary lectures regarding state-of-the-art clinical evaluation and treatments in oncology. As a selected participant the applicant presented a research abstract which was selected for publication and had the opportunity to present and discuss with the faculty clinical cases of thoracic cancer.
Personal skills and competences	
Mother tongue(s)	Italian
Other language(s)	English: excellent reading, writing, speaking
Organisational skills and competences	Experience in clinical trial participation according to GCP rules: -Participation as Co-Investigator to about 40 clinical trials in the field of thoracic oncology; - Principal Investigator of about 15 clinical trials in the field of thoracic oncology (Lung Cancer, Malignant Pleural Mesothelioma, Thymic malignancies). -Clinical and translational research projects design and
Awards and Grants	conduction.

- 2015: recipient of My First AIRC Grant for the translational project “MET-targeting in Small Cell Lung Cancer)
- 2014 ‘Saro Leggio’ award of the Associazione Italiana Ricerca Patologie Polmonari (AIRPP) for translational study of malignant pleural mesothelioma
- 2012: recipient of IMIG (International Mesothelioma Interest group) travel award
- 2010-2011: recipient of ESMO (European Society for Medical Oncology) translational research fellowship award for the project “Identification of novel molecular targets and biological agents for the chemotherapy of Malignant Pleural Mesothelioma”

List of publications:

IF:123,685 (15mar2017)

H INDEX : 9 (31dec2016)

FULL PAPER PUBLICATIONS IN PEER REVIEWED

JOURNALS WITH IMPACT FACTOR

1) **Pasello G**, Agata S, Bonaldi L, Corradin A, Montagna M, Zamarchi R, Parenti A, Cagol M, Zaninotto G, Ruol A, Ancona E, Amadori A and Saggioro D. “DNA copy number alterations correlate with survival of oesophageal adenocarcinoma patients”. Modern Pathology, 2009;22 (1):58-65.

IF: 5.485

2) Favaretto A, **Pasello G**, Magro C, Schettino C, Gridelli C. “Second and third line treatment in non-small-cell lung cancer”. Crit Rev Oncol Hematol, 2009; 71 (2):117-126

IF: 5.039

3) Favaretto A, **Pasello G**, Loreggian L, Breda C, Braccioni F, Marulli G, Stragliotto S, Magro C, Sotti G, Rea F. "Preoperative concomitant chemo-radiotherapy (CT-RT) in Superior Sulcus Tumor (SST): a mono-institutional experience". Lung Cancer, 2010 May; 68(2):228-33

IF: 3.767

4) **Pasello G** and Favaretto A. "Molecular targets in malignant pleural mesotelioma treatment". Current Drug Targets, 2009; 10: 1235-1244.

IF: 3.029

5) Sidi R*, **Pasello G***, Opitz I, Soltermann A, Tutic M, Rehrauer H, Weder W, Stahel RA, Felley-Bosco E.
**Equal contributors* "Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: An exploratory analysis". Eur J Cancer, 2011; 47 (2): 326-32.

IF: 6.163

6) Bonanno L, Schiavon M, Nardo G, Bertorelle R, Bonaldi L, Galligioni A, Indraccolo S, **Pasello G**, Rea F and Favaretto A. "Prognostic and Predictive Implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma". Anticancer Research 2010; 30: 5121-5128

IF: 1.895

7) Gridelli C, Morgillo F, Favaretto A, de Marinis F, Chella A, Cerea G, Mattioli R, Tortora G, Rossi A, Fasano M, **Pasello G**, Ricciardi S, Maione P, Di Maio M & Ciardiello F. "Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced

non-small-cell lung cancer: a randomized phase II study" *Annals of Oncology*, 2011; 22 (7): 1528-34

IF: 9.269

8) **Pasello G**, Nicotra S, Marulli G, Rea F, Bonanno L, Carli P, Magro C, Jirillo A, Favaretto A. "Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience" *Lung Cancer*, 2011;73: 351-355

IF: 3.767

9) Rumiato E, **Pasello G**, Montagna M, Scaini MC, De Salvo GL, Parenti A, Cagol M, Ruol A, Ancona E, Amadori A, Saggioro D. "DNA copy number profile discriminates between esophageal adenocarcinoma and squamous cell carcinoma and represents an independent prognostic parameter in esophageal adenocarcinoma". *Cancer Letters*, 2011; 310 (1): 84-9

IF: 5.992

10) Gridelli C, Gallo C, Morabito A, Iaffaioli RV, Favaretto A, Isa L, Barbera S, Gamucci T, Ceribelli A, Filipazzi V, Maione P, Rossi A, Barletta E, Signoriello S, De Maio E, Piccirillo MC, Di Maio M, Rocco G, Vecchione A, Perrone F; **G-STEP Investigators** "Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial" *J Thorac Oncol*. 2012 Jan;7(1):233-42

IF: 5.040

11) **Pasello G**, Ceresoli GL, Favaretto A "An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma". *Cancer Treat Rev*. 2013 Feb;39 (1):10-7

IF: 7.983

12) Di Maio M, Leigh NB, Gallo C, Feld R, Ciardiello F,

Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi F, Spatafora M, Ravaoli A, Felletti R, Fregoni V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C; **TORCH Investigators**. "Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer." J Thorac Oncol. 2012 Dec;7 (12):1830-4

IF: 5.040

13) **Pasello G**, Marulli G, Polo V, Breda C, Bonanno L, Loreggian L, Rea F, Favaretto A. "Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM)" Anticancer Res. 2012 Dec;32 (12):5393-9.

IF: 1.895

14) Marulli G, Di Chiara F, Braccioni F, Perissinotto E, **Pasello G**, Gino Favaretto A, Breda C, Rea F. "Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma" Eur J Cardiothorac Surg. 2013 Jul; 44 (1):104-10

IF: 2.803

15) **Pasello G**, Urso L, Conte P, Favaretto A. "Effects of Sulfonylureas on Tumor Growth: A Review of the Literature". The Oncologist 2013, 18(10):1118-1125

IF: 4.789

16) Ceresoli GL, Grosso F, Zucali PA, Mencoboni M, **Pasello G**, Ripa C, Degiovanni D, Simonelli M, Bruzzzone A, Dipietrantonj C, Piccolini E, Beretta GD, Favaretto AG, Giordano L, Santoro A, Botta M. "Prognostic factors in elderly patients with malignant pleural

mesothelioma: results of a multicenter survey.” Br J Cancer. 2014 Jul 15;111(2):220-6.

IF: 5.569

17) Marulli G, Verderi E, Zuin A, Schiavon M, Battistella L, Perissinotto E, Romanello P, Favaretto AG, **Pasello G**, Rea F. “Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.”

Interact Cardiovasc Thorac Surg. 2014 Aug;19(2):256-62

IF: 1.329

18) **Pasello G**, Urso L, Silic-Benussi M, Schiavon M, Cavallari I, Marulli G, Nannini N, Rea F, Ciminale V, Favaretto A. “Synergistic antitumor activity of recombinant human Apo2L/TRAIL in combination with Carboplatin and Pemetrexed in Malignant Pleural Mesothelioma”. J Thorac Oncol 2014, 2014

Jul;9(7):1008-17

IF: 5.040

19) Schiavon M, Marulli G, Nannini N, **Pasello G**, Lunardi F, Balestro E, Perissinotto E, Rebusso A, Saetta M, Rea F, Calabrese F. “COPD-related adenocarcinoma presents low aggressiveness morphological and molecular features compared to smoker tumours”.

Lung Cancer. 2014 Dec;86(3):311-7.

IF: 3.767

20) Marulli G, Battistella L, Perissinotto E, Breda C, Favaretto AG, **Pasello G**, Zuin A, Loreggian L, Schiavon M, Rea F.”Results of surgical resection after induction chemoradiation for Pancoast tumours †.”

Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):805-11

IF: 1.329

21) **Pasello G**, Carli P, Canova F, Bonanno L, Polo V, Zago G, Urso L, Conte P, Favaretto A. “Epirubicin plus

paclitaxel regimen as second-line treatment of patients with small-cell lung cancer.” Anticancer Res. 2015 Apr;35(4):2183-9.

IF: 1.895

22) Urso L, Calabrese F, Favaretto A, Conte PF and **Pasello G**. “Critical review about MDM2 in cancer: possible role in malignant mesothelioma and implications for treatment” Critical Review in Oncology and Hematology 2016 Jan;97:220-30

IF: 5.039

23) **Pasello G**, Urso L, Mencoboni M, Grosso F, Ceresoli GL, Lunardi F, Vuljan SE, Bertorelle R, Sacchetto V, Ciminale V, Rea F, Favaretto A, Conte PF, Calabrese F. “MDM2 and HIF1alpha expression levels in different histologic subtypes of Malignant Pleural Mesothelioma: correlation with pathological and clinical data.” Oncotarget, 2015 Dec 8;6(39):42053-66

IF: 5.008

24) Ferrazzi A, Russo I, **Pasello G**, Alaibac M. “Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature”. Exp Ther Med. 2016 Jan;11(1):197-200

IF: 1.56

25) Polo V, **Pasello G**, Frega S, Favaretto A, Koussis H, Conte P, Bonanno L.” Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization.” Oncotarget. 2016 May 3;7(18):25050-63

IF: 5.008

26) Frega S, Conte P, Fassan M, Polo V, **Pasello G**. A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib.

J Thorac Oncol. 2016 May;11(5):e63-4

IF: 5.040

27) Bonanno L, Zago G, Marulli G, Del Bianco P, Schiavon M, **Pasello G**, Polo V, Canova F, Tonetto F, Loreggian L, Rea F, Conte P, Favaretto A. "Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment."

Onco Targets Ther. 2016 Jun 21;9:3671-81

IF: 2.311

28) Valentina Polo, **Giulia Pasello**. "Multimodality treatment in limited small cell lung cancer (L-SCLC): different perspectives about the optimal approach" . Transl Cancer Res Vol 5, Supplement 2 (August 2016):

IF: 1.757

29) Russo I, Sacco G, Frega S, Polo V, **Pasello G**, Alaibac M. "Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab." Eur J Dermatol. 2017 Mar 1. doi: 10.1684/ejd.2016.2959.

IF: 2.069

30) Stefano Frega, Martina Lorenzi, Matteo Fassan, Stefano Indraccolo, Fiorella Calabrese, Adolfo Favaretto, Laura Bonanno, Valentina Polo, Giulia Zago, Francesca Lunardi, Ilaria Attili, Alberto Pavan, Massimo Rugge, Valentina Guarneri, PierFranco Conte, **Giulia Pasello**⁶. "Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations" Oncotarget March 2017 DOI: 10.18632/oncotarget.15945

IF: 5.008

FULL PAPER PUBLICATIONS IN PEER REVIEWED

JOURNALS WITHOUT IMPACT FACTOR

- 1) Favaretto AG, **Pasello G**, and Magro C
“Second and third line treatment in advanced non-small cell lung cancer”. Discovery Medicine, 2009; 8 (43): 204-209.
- 2) **Pasello G**, Altavilla G, Bonanno L, Rea F, Favaretto A.
“A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: a case report”. J Thorac Disease 2010; 2: 254-257.
- 3) Polo V, Zago G, Frega S, Canova F, Bonanno L, Favaretto A, Bonaldi L, Bertorelle R, Conte PF, **Pasello G**. “Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature” American Journal of Case Reports, Nov 3;16:782-9

BOOK CHAPTER

- **Giulia Pasello** and Adolfo Favaretto. Neoadjuvant Chemotherapy in Malignant Pleural Mesothelioma. Malignant Mesothelioma Chapter 5 December 2012. <http://dx.doi.org/10.5772/47880>
- Giovanni Luca Ceresoli, **Giulia Pasello**, Fiorella Calabrese. ESMO book: Thoracic Tumours – Essentials for Clinicians: Malignant Pleural Mesothelioma March 2014
- **Oncologia Edizione italiana a cura di Vittorina Zagonel** DE VITA - HELLMANN - LAWRENCE – ROSENBERG (Piccin)
- Participation as a speaker and scientific committee to several national and international

Additional information

conferences

- 2011- 2014 National AIOM (Associazione Italiana di Oncologia Medica) young working group elected member
- Reviewer of several peer reviewer journals focused on thoracic oncology
- Member of ASCO since 2008; member of ESMO and AIOM since 2009

I authorize the handling of my personal data according to Italian data protection Law.

PADOVA, 15/MAR/2017

